Aptose Biosciences Inc. has entered into a definitive agreement under which Hanmi Pharmaceutical Co. Ltd., through its wholly owned subsidiary HS North America Ltd., will acquire all outstanding common shares of Aptose not already owned by Hanmi or its affiliates. Minority shareholders of Aptose will receive C$2.41 in cash per share. Upon completion of the transaction, Aptose is expected to be delisted from all stock exchanges where its shares are currently listed, including the TSX. The agreement is intended to support the continued development of Aptose's TUS+VEN+AZA triplet therapy for acute myeloid leukemia, which has shown promising results in clinical studies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptose Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9578550-en) on November 19, 2025, and is solely responsible for the information contained therein.